Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome August 26, 2020 Source Science Translational Medicine
Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression July 9, 2020 Source Nature Communications
Zorevunersen (STK-001) demonstrates potential for disease modification, including reductions in seizures and improvements in cognition and behavior in children and adolescents with Dravet syndrome December 6, 2024 Source AES 2024
Patients with Dravet syndrome in open-label extension studies of zorevunersen (STK-001) have durable reductions in seizure frequency and ongoing improvements in cognition and behavior December 6, 2024 Source AES 2024
Small changes on the Vineland-3 are meaningful to caregivers of patients with Dravet syndrome December 6, 2024 Source AES 2024
Spectral EEG analysis demonstrates decreased slow-wave activity in patients with Dravet syndrome after treatment with zorevunersen (STK-001), an antisense oligonucleotide December 6, 2024 Source AES 2024
24-Month Analysis of BUTTERFLY A Prospective, Observational Study to Investigate Seizures and Comorbidities in Children and Adolescents with Dravet Syndrome September 10, 2024 Source EEC 2024